Tricuspid regurgitant jet velocity up in childhood cancer survivors

January 18, 2013
Tricuspid regurgitant jet velocity up in childhood cancer survivors
About one-quarter of adult survivors of childhood cancer who received chest-directed radiation therapy have increased tricuspid regurgitant jet velocity, according to research published online Jan. 7 in the Journal of Clinical Oncology.

(HealthDay)—About one-quarter of adult survivors of childhood cancer who received chest-directed radiation therapy (RT) have increased tricuspid regurgitant jet velocity (TRV), according to research published online Jan. 7 in the Journal of Clinical Oncology.

Gregory T. Armstrong, M.D., of St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues conducted a cross-sectional assessment involving 498 adult survivors of childhood cancer (median age, 38.0 years; median time from primary diagnosis, 27.3 years) to examine the prevalence of pulmonary hypertension, a late effect of cancer therapy.

The researchers found that 25.2 percent of survivors who received chest-directed RT and 30.8 percent of those who received more than 30 Gy had increased TRV. Increased TRV correlated with increasing dose of RT, more than 40 kg/m², and aortic valve regurgitation, in multivariate analysis. The odds of severe functional limitation on a six-minute walk were significantly increased for those with TRV more than 2.8 m/s versus those with a TRV ≤2.8 ms/s (odds ratio, 5.20).

"In conclusion, we identified an increased prevalence of TRV more than 2.8 m/s, which may indicate , in a large, well-characterized population of ," the authors write. "Increased risk was associated with chest-directed RT exposure, potentially mediated through both cardiac and pulmonary dysfunction."

Explore further: Neurocognitive deficits seen in survivors of pediatric Hodgkin's

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Neurocognitive deficits seen in survivors of pediatric Hodgkin's

September 10, 2012
(HealthDay)—Adult long-term survivors of childhood Hodgkin's lymphoma are at risk for neurocognitive impairment, according to research published online Sept. 4 in the Journal of Clinical Oncology.

Childhood cancer survivors are at high risk for multiple tumors as they age

June 27, 2011
The largest study yet of adult childhood cancer survivors found that the first cancer is just the beginning of a lifelong battle against different forms of the disease for about 10 percent of these survivors.

Long-term cardiac effects for childhood cancer survivors

March 7, 2012
(HealthDay) -- Regardless of exposure to cardiotoxic cancer therapies, survivors of childhood cancers display cardiovascular abnormalities and have markers of increased systemic inflammation and atherosclerotic disease, according ...

BMI and lean body mass decline after allogeneic HSCT

October 4, 2012
(HealthDay)—In survivors of childhood hematologic malignancies who have received allogeneic hematopoietic stem cell transplantation (alloHSCT), body mass index (BMI) decreases significantly, mainly due to a reduction in ...

Recommended for you

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.